PriceTargets.com logo

Neumora Therapeutics - NMRA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.71
  • Forecasted Upside: 154.33%
  • Number of Analysts: 10
  • Breakdown:
  • 3 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$2.64 As of 03/18/2026 05:00 PM ET
▼ -0.19 (-6.71%)

This chart shows the closing price for NMRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neumora Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NMRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NMRA

Analyst Price Target is $6.71
▲ +154.33% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Neumora Therapeutics in the last 3 months. The average price target is $6.71, with a high forecast of $14.00 and a low forecast of $1.00. The average price target represents a 154.33% upside from the last price of $2.64.

This chart shows the closing price for NMRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Neumora Therapeutics. This rating has held steady since February 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 3 sell ratings
Ratings as of
2/17/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 3 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/17/2026William BlairUpgradeMarket Perform ➝ Outperform
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/12/2026Leerink PartnersUpgradeStrong-Buy
1/12/2026Leerink PartnersInitiated CoverageOutperform$8.00
1/5/2026MizuhoSet Target$6.00
12/1/2025Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$4.00 ➝ $7.00
11/17/2025Stifel NicolausBoost TargetHold ➝ Hold$2.00 ➝ $3.00
10/28/2025Needham & Company LLCBoost TargetBuy ➝ Buy$6.00 ➝ $8.00
10/27/2025GuggenheimUpgradeNeutral ➝ Buy$14.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/16/2025JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
7/16/2025MizuhoBoost TargetOutperform ➝ Outperform$4.00 ➝ $5.00
5/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/2/2025Bank of AmericaReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.00
3/10/2025William BlairDowngradeOutperform ➝ Market Perform
3/7/2025GuggenheimDowngradeBuy ➝ Neutral
3/7/2025Stifel NicolausDowngradeBuy ➝ Hold$6.00 ➝ $2.00
3/4/2025Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$4.00 ➝ $4.00
3/4/2025HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $18.00
3/4/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
2/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
1/15/2025William BlairReiterated RatingOutperform
1/6/2025Bank of AmericaLower TargetBuy ➝ Buy$22.00 ➝ $7.00
1/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
1/2/2025Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$29.00 ➝ $4.00
1/2/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
12/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/22/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
11/5/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $15.00
10/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
10/1/2024HC WainwrightInitiated CoverageBuy$30.00
9/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
9/4/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
7/22/2024Needham & Company LLCInitiated CoverageBuy$23.00
7/8/2024MizuhoInitiated CoverageOutperform$20.00
4/12/2024William BlairReiterated RatingOutperform
3/28/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$31.00
3/18/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$20.00 ➝ $22.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$13.00
11/8/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$21.00 ➝ $20.00
10/10/2023JPMorgan Chase & Co.Initiated CoverageOverweight$21.00
10/10/2023Bank of AmericaInitiated CoverageBuy$18.00
10/10/2023William BlairInitiated CoverageOutperform ➝ Outperform$26.00
10/10/2023GuggenheimInitiated CoverageBuy$22.00
10/10/2023Royal Bank Of CanadaInitiated CoverageOutperform$24.00
10/10/2023Stifel NicolausInitiated CoverageBuy$26.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/20/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 7 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 13 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 13 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Neumora Therapeutics logo
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $2.64
Low: $2.63
High: $2.82

50 Day Range

MA: $2.69
Low: $1.87
High: $3.59

52 Week Range

Now: $2.64
Low: $0.61
High: $3.65

Volume

790,237 shs

Average Volume

870,515 shs

Market Capitalization

$441.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Neumora Therapeutics?

The following Wall Street research analysts have issued research reports on Neumora Therapeutics in the last twelve months: Bank of America Corporation, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Royal Bank Of Canada, Stifel Nicolaus, Weiss Ratings, and William Blair.
View the latest analyst ratings for NMRA.

What is the current price target for Neumora Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Neumora Therapeutics in the last year. Their average twelve-month price target is $6.71, suggesting a possible upside of 154.3%. Guggenheim has the highest price target set, predicting NMRA will reach $14.00 in the next twelve months. Bank of America Corporation has the lowest price target set, forecasting a price of $1.00 for Neumora Therapeutics in the next year.
View the latest price targets for NMRA.

What is the current consensus analyst rating for Neumora Therapeutics?

Neumora Therapeutics currently has 3 sell ratings, 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NMRA, but not buy more shares or sell existing shares.
View the latest ratings for NMRA.

What other companies compete with Neumora Therapeutics?

Other companies that are similar to Neumora Therapeutics include MANE, Oruka Therapeutics, Tyra Biosciences, Ocular Therapeutix and Stoke Therapeutics. Learn More about companies similar to Neumora Therapeutics.

How do I contact Neumora Therapeutics' investor relations team?

The company's listed phone number is 857-760-0900 and its investor relations email address is [email protected]. The official website for Neumora Therapeutics is neumoratx.com. Learn More about contacing Neumora Therapeutics investor relations.